Chronic Lymphocytic Leukemia

In a phase 2 study, adding venetoclax to ibrutinib rendered BTK C481X resistance mutations undetectable in patients with CLL.

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

A retrospective analysis of 3234 patients with CLL/SLL showed that over half of those 75 to 79 years of age went on to receive second-line therapy.

A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.

Fixed-duration pirtobrutinib plus venetoclax and rituximab reduced the risk of progression or death by 45% in previously treated CLL.

Fixed-duration venetoclax/obinutuzumab more than doubled median PFS vs chlorambucil/obinutuzumab in previously untreated CLL.

Sonrotoclax plus zanubrutinib drove durable remissions across IGHV-mutated and del(17p)/TP53 CLL subgroups in an updated phase 1/1b analysis.

First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Suchitra Sundaram, MD, discusses the assortment of therapies available in chronic lymphocytic leukemia and frontline approaches.

Ibrutinib/Rituximab Preserves QOL vs FCR in Previously Untreated CLL

Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Pirtobrutinib plus venetoclax and rituximab improved PFS in relapsed/refractory CLL/SLL, meeting the primary end point of BRUIN CLL-322.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

Jennifer R. Brown, MD, PhD, discusses the design of the AMPLIFY trial and safety data for acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.